Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
18. Dezember 2023 09:15 ET
|
Theralink Technologies, Inc.
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse...
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
20. Juni 2019 08:30 ET
|
Celsion CORP
An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range...